Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Dividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ani Pharmaceuticals (ANIP) Depreciation and Depletion: 2012-2024

Historic Depreciation and Depletion for Ani Pharmaceuticals (ANIP) over the last 13 years, with Dec 2024 value amounting to $7.4 million.

  • Ani Pharmaceuticals' Depreciation and Depletion rose 8.33% to $1.3 million in Q4 2020 from the same period last year, while for Dec 2020 it was $4.9 million, marking a year-over-year increase of 6.52%. This contributed to the annual value of $7.4 million for FY2024, which is 1.33% down from last year.
  • According to the latest figures from FY2024, Ani Pharmaceuticals' Depreciation and Depletion is $7.4 million, which was down 1.33% from $7.5 million recorded in FY2023.
  • In the past 5 years, Ani Pharmaceuticals' Depreciation and Depletion registered a high of $7.5 million during FY2023, and its lowest value of $4.8 million during FY2020.
  • For the 3-year period, Ani Pharmaceuticals' Depreciation and Depletion averaged around $7.4 million, with its median value being $7.4 million (2024).
  • In the last 5 years, Ani Pharmaceuticals' Depreciation and Depletion spiked by 34.55% in 2022 and then dropped by 1.33% in 2024.
  • Ani Pharmaceuticals' Depreciation and Depletion (Yearly) stood at $4.8 million in 2020, then grew by 14.58% to $5.5 million in 2021, then soared by 34.55% to $7.4 million in 2022, then increased by 1.35% to $7.5 million in 2023, then dropped by 1.33% to $7.4 million in 2024.